HealthEquity (HQY) has drawn investor attention after announcing the termination of Chief Technology Officer Eli Rosner without cause, effective April 17, 2026. Technology oversight will shift to Executive Vice President Sunil Rajasekar.

The leadership changes come after a 1 day share price return of 7.41% decline and extend a 90 day share price return of 17.2% decline. However, the 3 year total shareholder return of 36.58% shows that longer term holders have still seen gains.

If this kind of management reshuffle has you thinking about where else growth stories could emerge in healthcare technology, it may be worth scanning for other healthcare names riding similar themes using the 31 healthcare AI stocks.

With HealthEquity shares down over the past year and trading at a sizable discount to both analyst targets and some intrinsic estimates, investors now face a key question: is this a genuine value gap or is future growth already reflected in the price?

Most Popular Narrative: 30.9% Undervalued

Simply Wall St's most followed narrative puts HealthEquity's fair value at $112.88 versus a last close of $77.96, framing a sizeable valuation gap for investors to assess.

The recent regulatory expansion, allowing direct primary care, pre deductible telehealth, and millions of new ACA bronze or catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades, poised to accelerate new account openings and AUM growth, meaningfully boosting future revenue.

Want to see what sits behind that growth story and valuation gap? Revenue compounding, margin expansion and a punchy future earnings multiple all sit at the core of this fair value call.

Result: Fair Value of $112.88 (UNDERVALUED)

However, that upside story could be challenged if a weaker labor market slows new HSA account growth or if lower interest rates reduce yields on custodial cash.

Another Take: Multiples Paint a Tougher Picture

While the popular narrative sees HealthEquity trading below fair value, the P/E data tell a different story. At 30.6x earnings versus a fair ratio of 25.7x, and compared with 17.4x for peers and 22.6x for the broader US Healthcare group, the shares look expensive on this yardstick. For you, the tension is simple: is the premium a sign of quality or a valuation risk waiting to reset?

Next Steps

With mixed signals on value and growth, the real question is how you see the risk reward balance, so take a closer look at the 4 key rewards

Looking for more investment ideas?

If HealthEquity is on your radar, do not stop there. The wider market is full of other potential opportunities you will not want to miss.

• Spot potential bargains by scanning companies that look mispriced on quality and value using the 58 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with stronger finances through the solid balance sheet and fundamentals stocks screener (41 results).
• Hunt for under followed names that still have robust fundamentals with the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.